Despite indications that a gout pill is associated with an increased risk of heart attack and death, the Food and Drug Administration is allowing the medicine to remain on the market, but will require the label to carry a so-called Black Box, the most serious warning about the risk of a medication.

In explaining its decision, the agency maintained that the drug, called Urolic, may benefit some of the roughly 8.3 million Americans who suffer from this form of arthritis. Gout occurs when too much uric acid crystallizes and forms deposits in the joints, causing acute episodes of extreme pain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Janet Woodcock, who heads the FDA Center for Drug Evaluation and Research, wrote that Uloric “remains the only alternative to allopurinol,” noting that some patients suffer serious skin reactions and liver damage from allopurinol.

    Only alternative? What about colchicine?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy